Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]FP-TZTP is a subtype-selective muscarinic cholinergic radioligand with M2 selectivity, developed for positron emission tomography (PET) imaging. It has potential applications in studying Alzheimer's disease and other neurodegenerative conditions. The tracer shows rapid uptake in the brain with distribution consistent with M2 cholinergic receptors, being similar in cortical regions, basal ganglia, and thalamus, but significantly lower in the cerebellum. Studies have demonstrated that [18F]FP-TZTP binding can be blocked by unlabeled FP-TZTP, indicating specific binding to muscarinic receptors. The tracer is also sensitive to changes in brain acetylcholine levels, as demonstrated in studies using physostigmine, an acetylcholinesterase inhibitor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]FP-TZTP.